Nkarta (NKTX) Share-based Compensation (2019 - 2026)
Nkarta (NKTX) posted quarterly Share-based Compensation of $12.0 million for Q1 2026, up 323.43% year-over-year from $2.8 million in Q1 2025, and up 318.06% quarter-over-quarter from -$5.5 million in Q4 2025.
Nkarta (NKTX) Share-based Compensation (2019 - 2026) Analysis & Trends
Nkarta's Share-based Compensation history runs 8 years deep, the most recent figure standing at $12.0 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 323.43% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (down 21.04% YoY), while the FY2025 annual figure was $10.7 million, down 44.85% from the prior year.
- Share-based Compensation for Q1 2026 stood at $12.0 million, up from -$5.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $12.1 million in Q3 2025, with the low at -$5.5 million in Q4 2025.
- The 5-year median for Share-based Compensation is $4.3 million (2023), against an average of $4.4 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 241.32% in 2025, then surged 323.43% in 2026.
- Nkarta's Share-based Compensation stood at $4.5 million in 2022, then retreated by 21.2% to $3.5 million in 2023, then advanced by 10.88% to $3.9 million in 2024, then plunged by 241.32% to -$5.5 million in 2025, then jumped by 318.06% to $12.0 million in 2026.
- Business Quant data shows NKTX's Share-based Compensation at $12.0 million in Q1 2026, -$5.5 million in Q4 2025, and $12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | - |
| 10 | Nkarta | 195.55 Mn | 195.55 Mn | - | 11.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.10 Mn |
| Jun 30, 2026 | 11.10 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | 12.10 Mn |
| Sep 30, 2025 | 12.10 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.37 Mn |